百利天恒上半年净亏损11.18亿元 多款创新药研发取得进展

Core Viewpoint - 百利天恒 reported a significant decline in revenue and a shift to net loss in the first half of 2025, primarily due to high R&D investments and the absence of prior year income from a major collaboration with BMS [1][2] Financial Performance - The company achieved revenue of 171 million yuan in the first half of 2025, a year-on-year decrease of 96.92% [1] - The net profit attributable to shareholders was -1.118 billion yuan, marking a transition from profit to loss compared to the previous year [1] - Basic earnings per share were -2.79 yuan [1] R&D Investment - R&D expenses for the first half of 2025 amounted to 1.039 billion yuan, reflecting a year-on-year increase of 90.74% [2] - The company has 15 innovative drugs in clinical trials, with 2 drugs in the IND acceptance stage and 3 drugs in Phase III registration clinical trials [2] Clinical Trials and Drug Development - The company is conducting nearly 90 clinical trials, with around 80 in China and 10 in the United States [2] - In the chemical drug and traditional Chinese medicine sectors, the company holds 208 chemical drug registration certificates, 20 chemical raw material drug registration certificates, and 30 traditional Chinese medicine registration certificates [2] Key Clinical Trial Progress - The company successfully completed patient enrollment for 7 Phase III clinical trials, including 5 for the drug iza-bren [3] - Iza-bren is a first-in-class EGFR×HER3 bispecific ADC, with over 40 clinical trials ongoing for various cancer types in China and the U.S. [3] - A Phase III clinical trial for iza-bren in treating recurrent or metastatic nasopharyngeal carcinoma has met its primary endpoint [4]